|
US8053191B2
(en)
|
2006-08-31 |
2011-11-08 |
Westend Asset Clearinghouse Company, Llc |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
EP2625292B1
(en)
|
2010-10-07 |
2018-12-05 |
The General Hospital Corporation |
Biomarkers of cancer
|
|
WO2012064975A1
(en)
|
2010-11-12 |
2012-05-18 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
CN103502448B
(zh)
|
2010-11-12 |
2017-03-29 |
Gen9股份有限公司 |
核酸合成的方法和设备
|
|
CA2831144A1
(en)
|
2011-03-23 |
2012-09-27 |
Pioneer Hi-Bred International, Inc. |
Methods for producing a complex transgenic trait locus
|
|
JP6214530B2
(ja)
|
2011-07-15 |
2017-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
転写活性化因子様エフェクターの組立て方法
|
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
LT2944693T
(lt)
|
2011-08-26 |
2019-08-26 |
Gen9, Inc. |
Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
|
|
EP3604555B1
(en)
|
2011-10-14 |
2024-12-25 |
President and Fellows of Harvard College |
Sequencing by structure assembly
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
CA2871505C
(en)
|
2012-04-24 |
2021-10-12 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
IL236303B
(en)
|
2012-06-25 |
2022-07-01 |
Gen9 Inc |
Methods for high-throughput nucleic acid assembly and sequencing
|
|
EP3789405A1
(en)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
CA2898184A1
(en)
|
2013-01-16 |
2014-07-24 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
EP2954042B1
(en)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
EP2971184B1
(en)
|
2013-03-12 |
2019-04-17 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
RU2662932C2
(ru)
|
2013-03-14 |
2018-07-31 |
Карибо Биосайенсиз, Инк. |
Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
SG10201913068PA
(en)
|
2013-06-04 |
2020-02-27 |
Harvard College |
Rna-guided transcriptional regulation
|
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
|
WO2014197748A2
(en)
*
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
CN120574876A
(zh)
*
|
2013-08-22 |
2025-09-02 |
纳幕尔杜邦公司 |
使用向导rna/cas内切核酸酶系统的植物基因组修饰及其使用方法
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
EP3988649B1
(en)
|
2013-09-18 |
2024-11-27 |
Kymab Limited |
Methods, cells and organisms
|
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3835419A1
(en)
*
|
2013-12-12 |
2021-06-16 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CA2935032C
(en)
*
|
2013-12-26 |
2024-01-23 |
The General Hospital Corporation |
Multiplex guide rnas
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
EP3690044B1
(en)
|
2014-02-11 |
2024-01-10 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
|
US11028388B2
(en)
|
2014-03-05 |
2021-06-08 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
EP3122880B1
(en)
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
EP3540061A1
(en)
|
2014-04-02 |
2019-09-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
JP2017512481A
(ja)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ |
Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
|
|
WO2015184259A1
(en)
|
2014-05-30 |
2015-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods to treat latent viral infections
|
|
CN106604994B
(zh)
|
2014-06-23 |
2021-12-14 |
通用医疗公司 |
通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
|
|
EP3161159B1
(en)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
US20150376586A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
US20170198268A1
(en)
*
|
2014-07-09 |
2017-07-13 |
Gen9, Inc. |
Compositions and Methods for Site-Directed DNA Nicking and Cleaving
|
|
US10676754B2
(en)
|
2014-07-11 |
2020-06-09 |
E I Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
WO2016022866A1
(en)
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
|
|
MX2017002930A
(es)
|
2014-09-12 |
2017-06-06 |
Du Pont |
Generacion de sitios de integracion especifica de sitio para loci de rasgos complejos en maiz y soja, y metodos de uso.
|
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US20170233762A1
(en)
*
|
2014-09-29 |
2017-08-17 |
The Regents Of The University Of California |
Scaffold rnas
|
|
AU2015330699B2
(en)
*
|
2014-10-10 |
2021-12-02 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
EP3215623A4
(en)
|
2014-11-06 |
2018-09-26 |
President and Fellows of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
EP4464338A3
(en)
|
2014-11-07 |
2025-02-12 |
Editas Medicine, Inc. |
Systems for improving crispr/cas-mediated genome-editing
|
|
CN107109486B
(zh)
*
|
2014-11-14 |
2021-08-13 |
基础科学研究院 |
用于检测基因组中遗传剪刀的脱靶位点的方法
|
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
|
CN104531633A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
Cas9-scForkI融合蛋白及其应用
|
|
JP2017534294A
(ja)
*
|
2014-11-19 |
2017-11-24 |
インスティチュート フォー ベーシック サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ |
二つのベクターから発現されたｃａｓ９タンパク質を利用した遺伝子発現調節方法
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
WO2016090385A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Applied Stemcell, Inc. |
Site-directed crispr/recombinase compositions and methods of integrating transgenes
|
|
CN116059378A
(zh)
|
2014-12-10 |
2023-05-05 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094872A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
CA2970683A1
(en)
*
|
2014-12-18 |
2016-06-23 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
US20180179523A1
(en)
*
|
2014-12-18 |
2018-06-28 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
US10190106B2
(en)
*
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
|
US9650617B2
(en)
|
2015-01-28 |
2017-05-16 |
Pioneer Hi-Bred International. Inc. |
CRISPR hybrid DNA/RNA polynucleotides and methods of use
|
|
EP3250689B1
(en)
*
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
WO2016130600A2
(en)
*
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
US10640781B2
(en)
|
2015-02-18 |
2020-05-05 |
Iowa State University Research Foundation, Inc. |
Modification of transcriptional repressor binding site in NF-YC4 promoter for increased protein content and resistance to stress
|
|
KR20230156800A
(ko)
|
2015-03-03 |
2023-11-14 |
더 제너럴 하스피탈 코포레이션 |
변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
|
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
EA201792663A1
(ru)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
|
|
WO2016196282A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
CN108026526B
(zh)
|
2015-06-09 |
2023-05-12 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
|
EP3308168B1
(en)
*
|
2015-06-10 |
2020-04-01 |
Firmenich SA |
Cell lines for screening odorant and aroma receptors
|
|
US20160362705A1
(en)
|
2015-06-12 |
2016-12-15 |
Lonza Walkersville, Inc. |
Methods for Nuclear Reprogramming Using Synthetic Transcription Factors
|
|
WO2016205276A1
(en)
|
2015-06-15 |
2016-12-22 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
US11279928B2
(en)
*
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
JP7044373B2
(ja)
|
2015-07-15 |
2022-03-30 |
ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー |
ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
US20180230450A1
(en)
*
|
2015-08-03 |
2018-08-16 |
President And Fellows Of Harvard College |
Cas9 Genome Editing and Transcriptional Regulation
|
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
|
WO2017035416A2
(en)
*
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
JP6799586B2
(ja)
|
2015-08-28 |
2020-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017040511A1
(en)
*
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
|
WO2017044843A1
(en)
*
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
EP3353296B1
(en)
|
2015-09-24 |
2020-11-04 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
JP2018529353A
(ja)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
配列決定法による切断事象の包括的生体外報告（ＣＩＲＣＬＥ−ｓｅｑ）
|
|
WO2017061805A1
(ko)
*
|
2015-10-06 |
2017-04-13 |
기초과학연구원 |
식물 원형질체로부터 유전체 교정 식물체를 고효율로 제조하는 방법
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017070598A1
(en)
|
2015-10-23 |
2017-04-27 |
Caribou Biosciences, Inc. |
Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
AU2016349288A1
(en)
|
2015-11-03 |
2018-05-31 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
|
EP3374501B1
(en)
|
2015-11-11 |
2023-07-12 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
|
US11542495B2
(en)
|
2015-11-20 |
2023-01-03 |
Sage Science, Inc. |
Preparative electrophoretic method for targeted purification of genomic DNA fragments
|
|
JP6500293B2
(ja)
*
|
2015-11-25 |
2019-04-17 |
国立大学法人群馬大学 |
Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法
|
|
KR102787119B1
(ko)
|
2015-11-30 |
2025-03-27 |
듀크 유니버시티 |
유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
|
|
WO2017106251A1
(en)
*
|
2015-12-14 |
2017-06-22 |
President And Fellows Of Harvard College |
Cas discrimination using tuned guide rna
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
MX2018007987A
(es)
*
|
2015-12-28 |
2019-01-10 |
Novartis Ag |
Composiciones y metodos para el tratamiento de hemoglobinopatias.
|
|
IL260532B2
(en)
|
2016-01-11 |
2023-12-01 |
Univ Leland Stanford Junior |
Chimeric proteins- containing systems and uses thereof in regulating gene expression
|
|
MX2018008345A
(es)
|
2016-01-11 |
2018-12-06 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia.
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
EP4155397B1
(en)
|
2016-02-10 |
2024-06-26 |
The Regents of The University of Michigan |
Detection of nucleic acids
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017151444A1
(en)
*
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
|
CN115927299A
(zh)
*
|
2016-03-15 |
2023-04-07 |
核糖核酸复兴股份有限责任公司 |
增加双链rna产生的方法和组合物
|
|
CN109414414A
(zh)
|
2016-03-16 |
2019-03-01 |
戴维·格拉德斯通研究所 |
用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
|
CN106701765A
(zh)
*
|
2016-04-11 |
2017-05-24 |
广东赤萌医疗科技有限公司 |
用于hiv感染治疗的多核苷酸及其制备药物应用
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
|
EP4613756A3
(en)
|
2016-04-25 |
2025-11-12 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
|
CN107326046A
(zh)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
一种提高外源基因同源重组效率的方法
|
|
CN113831407B
(zh)
|
2016-05-20 |
2024-06-11 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
CA3209273A1
(en)
*
|
2016-06-02 |
2017-12-07 |
Sigma-Aldrich Co. Llc |
Using programmable dna binding proteins to enhance targeted genome modification
|
|
US20190100732A1
(en)
|
2016-06-02 |
2019-04-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Assay for the removal of methyl-cytosine residues from dna
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
WO2017217768A1
(ko)
*
|
2016-06-15 |
2017-12-21 |
주식회사 툴젠 |
온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도
|
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
WO2018005445A1
(en)
|
2016-06-27 |
2018-01-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
|
ES2817973T3
(es)
|
2016-07-01 |
2021-04-08 |
Microsoft Technology Licensing Llc |
Almacenamiento a través de la edición iterativa del ADN
|
|
MA45670A
(fr)
*
|
2016-07-13 |
2019-05-22 |
Vertex Pharma |
Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
|
|
CN109477086A
(zh)
*
|
2016-07-13 |
2019-03-15 |
陈奇涵 |
一种基因组dna特异性编辑方法和应用
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
CN109790527A
(zh)
*
|
2016-07-26 |
2019-05-21 |
通用医疗公司 |
普氏菌属和弗朗西斯氏菌属的CRISPR1(Cpf1)的变体
|
|
EP3492096A4
(en)
*
|
2016-07-28 |
2020-04-15 |
Institute for Basic Science |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH CAS9 PROTEINS AND GUIDE RNA
|
|
JP2019523009A
(ja)
|
2016-07-29 |
2019-08-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
|
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
WO2018031683A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
JP6799066B2
(ja)
|
2016-08-10 |
2020-12-09 |
株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ |
真核細胞のゲノムの標的部位を改変する方法及び標的部位における検出対象核酸配列の存在又は非存在を検出する方法
|
|
CA3034369A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Whitehead Institute For Biomedical Research |
Methods of editing dna methylation
|
|
SG11201901306XA
(en)
*
|
2016-08-19 |
2019-03-28 |
Toolgen Inc |
Artificially engineered angiogenesis regulatory system
|
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
|
EP3995574A1
(en)
|
2016-08-24 |
2022-05-11 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CN118853848A
(zh)
|
2016-08-31 |
2024-10-29 |
哈佛学院董事及会员团体 |
将生物分子的检测组合到使用荧光原位测序的单个试验的方法
|
|
US20190255106A1
(en)
*
|
2016-09-07 |
2019-08-22 |
Flagship Pioneering Inc. |
Methods and compositions for modulating gene expression
|
|
WO2018048194A1
(ko)
*
|
2016-09-07 |
2018-03-15 |
울산대학교 산학협력단 |
dCas9 단백질 및 표적 핵산 서열에 결합하는 gRNA를 이용한 핵산 검출의 민감도 및 특이도 향상용 조성물 및 방법
|
|
CN107880132B
(zh)
*
|
2016-09-30 |
2022-06-17 |
北京大学 |
一种融合蛋白及使用其进行同源重组的方法
|
|
CA3036926C
(en)
*
|
2016-09-30 |
2022-05-31 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
MX2019003674A
(es)
|
2016-09-30 |
2021-01-08 |
Univ California |
Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
|
KR20260019012A
(ko)
|
2016-10-07 |
2026-02-09 |
인티그레이티드 디엔에이 테크놀로지스 아이엔씨. |
Ｓ. 피오게네스 ｃａｓ９ 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
|
|
KR20190067209A
(ko)
*
|
2016-10-14 |
2019-06-14 |
더 제너럴 하스피탈 코포레이션 |
후성적으로 조절되는 부위-특이적 뉴클레아제
|
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
US20180282722A1
(en)
*
|
2016-11-21 |
2018-10-04 |
Massachusetts Institute Of Technology |
Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
|
|
KR20190082318A
(ko)
|
2016-11-22 |
2019-07-09 |
인티그레이티드 디엔에이 테크놀로지스 아이엔씨. |
Crispr/cpf1 시스템 및 방법
|
|
SG10202106058WA
(en)
|
2016-12-08 |
2021-07-29 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
WO2018111947A1
(en)
|
2016-12-12 |
2018-06-21 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
|
US20200149039A1
(en)
|
2016-12-12 |
2020-05-14 |
Whitehead Institute For Biomedical Research |
Regulation of transcription through ctcf loop anchors
|
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
|
EP3555297A1
(en)
|
2016-12-19 |
2019-10-23 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
TWI851534B
(zh)
*
|
2016-12-22 |
2024-08-11 |
美商英特利亞醫療公司 |
用於治療α-１抗胰蛋白酶缺乏症之組合物及方法
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
EP3562942A4
(en)
*
|
2016-12-28 |
2020-12-09 |
Ionis Pharmaceuticals, Inc. |
MODIFIED CRISPR-RNA AND ITS USES
|
|
EP3565608A4
(en)
|
2017-01-05 |
2020-12-16 |
Rutgers, The State University of New Jersey |
TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
|
|
JP7229923B2
(ja)
|
2017-01-06 |
2023-02-28 |
エディタス・メディシン、インコーポレイテッド |
ヌクレアーゼ切断を評価する方法
|
|
DK3565891T3
(da)
|
2017-01-09 |
2023-07-24 |
Whitehead Inst Biomedical Res |
Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
|
|
EP3572525A4
(en)
*
|
2017-01-17 |
2020-09-30 |
Institute for Basic Science |
PROCEDURE FOR IDENTIFYING AN OFF-TARGET BASIC EDITING SITE BY BREAKING A SINGLE DNA STRAND
|
|
RU2019126483A
(ru)
|
2017-01-23 |
2021-02-24 |
Ридженерон Фармасьютикалз, Инк. |
Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
JP2020507312A
(ja)
|
2017-02-10 |
2020-03-12 |
ザイマージェン インコーポレイテッド |
複数の宿主用の複数のｄｎａコンストラクトのアセンブリ及び編集のためのモジュラーユニバーサルプラスミド設計戦略
|
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
WO2018165309A1
(en)
|
2017-03-08 |
2018-09-13 |
The Regents Of The University Of Michigan |
Analyte detection
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
CN108660161B
(zh)
*
|
2017-03-31 |
2023-05-09 |
中国科学院脑科学与智能技术卓越创新中心 |
基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法
|
|
CN110506203A
(zh)
*
|
2017-04-07 |
2019-11-26 |
塞奇科学股份有限公司 |
用于通过使用集成电泳dna纯化来检测遗传结构变异的系统和方法
|
|
EP3609521A4
(en)
|
2017-04-14 |
2021-06-16 |
University of Massachusetts |
TARGETING OF CELL TROPISM RECEPTORS TO INHIBIT INFECTION BY THE CYTOMEGALOVIRUS
|
|
US11591589B2
(en)
|
2017-04-21 |
2023-02-28 |
The General Hospital Corporation |
Variants of Cpf1 (Cas12a) with altered PAM specificity
|
|
WO2018195540A1
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Inducible, tunable, and multiplex human gene regulation using crispr-cpf1
|
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
EP3630849A4
(en)
|
2017-05-25 |
2021-01-13 |
The General Hospital Corporation |
BIPARTITE BASIC EDITOR (BBE) AND TYPE II-C-CAS9 ZINC FINGER EDITOR ARCHITECTURES
|
|
US10738284B2
(en)
|
2017-06-05 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
B4GALT1 cDNA variants and compositions comprising the same
|
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
|
MX2019014640A
(es)
|
2017-06-09 |
2020-10-05 |
Editas Medicine Inc |
Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
|
|
KR102634727B1
(ko)
|
2017-06-14 |
2024-02-07 |
위스콘신 얼럼나이 리서어치 화운데이션 |
변형된 가이드 rna, crispr-리보뉴클레오프로테인 복합체 및 사용 방법
|
|
WO2018232356A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US20200140896A1
(en)
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
|
KR102655021B1
(ko)
|
2017-07-11 |
2024-04-04 |
시그마-알드리치 컴퍼니., 엘엘씨 |
표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
EP3585161A1
(en)
|
2017-07-31 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
EP3663310A4
(en)
|
2017-08-04 |
2021-08-11 |
Peking University |
TALE RVD SPECIFICALLY RECOGNIZING A DNA BASE MODIFIED BY METHYLATION AND CORRESPONDING APPLICATION
|
|
WO2019028686A1
(zh)
|
2017-08-08 |
2019-02-14 |
北京大学 |
基因敲除方法
|
|
CA3073448A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
US20190098879A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
|
|
WO2019075197A1
(en)
|
2017-10-11 |
2019-04-18 |
The General Hospital Corporation |
METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
CN107602707B
(zh)
*
|
2017-10-17 |
2021-04-23 |
湖北大学 |
一种特异性调节枯草芽孢杆菌外源基因表达的dcas9-ω融合蛋白及其应用
|
|
JP7101419B2
(ja)
|
2017-10-27 |
2022-07-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
内因性ｔ細胞受容体の標的置換
|
|
WO2019089884A2
(en)
*
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
|
CN120310773A
(zh)
*
|
2017-11-16 |
2025-07-15 |
阿斯利康(瑞典)有限公司 |
用于改善基于Cas9的敲入策略的有效性的组合物和方法
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
EP3728589A4
(en)
*
|
2017-12-22 |
2021-11-03 |
G+Flas Life Sciences |
CHEMICAL GENOMIC ENGINEERING MOLECULES AND PROCESSES
|
|
EP3740580A4
(en)
|
2018-01-19 |
2021-10-20 |
Duke University |
GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
|
|
CN109504711A
(zh)
*
|
2018-02-14 |
2019-03-22 |
复旦大学 |
基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法
|
|
US11718849B2
(en)
|
2018-02-19 |
2023-08-08 |
Agilent Technologies, Inc. |
Phosphopeptide-encoding oligonucleotide libraries and methods for detecting phosphorylation-dependent molecular interactions
|
|
WO2019165168A1
(en)
|
2018-02-23 |
2019-08-29 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
KR102907245B1
(ko)
|
2018-03-14 |
2026-01-05 |
에디타스 메디신, 인코포레이티드 |
혈색소병증 치료를 위한 시스템 및 방법
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
JP7522038B2
(ja)
|
2018-04-06 |
2024-07-24 |
ザ チルドレンズ メディカル センター コーポレーション |
体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
|
|
US11898203B2
(en)
|
2018-04-17 |
2024-02-13 |
The General Hospital Corporation |
Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents
|
|
KR102922694B1
(ko)
|
2018-04-19 |
2026-02-03 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
유전자 편집을 위한 조성물 및 방법
|
|
WO2019213430A1
(en)
*
|
2018-05-03 |
2019-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for nicking target dna sequences
|
|
CN108588123A
(zh)
*
|
2018-05-07 |
2018-09-28 |
南京医科大学 |
CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
|
|
AU2019265019B2
(en)
|
2018-05-11 |
2025-11-06 |
Beam Therapeutics Inc. |
Methods of substituting pathogenic amino acids using programmable base editor systems
|
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3575396A1
(en)
*
|
2018-06-01 |
2019-12-04 |
Algentech SAS |
Gene targeting
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
CN110592141B
(zh)
|
2018-06-13 |
2023-07-07 |
中国科学院上海有机化学研究所 |
用于调控基因编辑效率的化合物及其应用
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
|
CA3107002A1
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
Applications of crispri in high throughput metabolic engineering
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
AU2019326408A1
(en)
|
2018-08-23 |
2021-03-11 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
CN112654702B
(zh)
|
2018-09-07 |
2025-05-13 |
阿斯利康(瑞典)有限公司 |
改进的核酸酶的组合物和方法
|
|
WO2020072250A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
|
|
WO2020072254A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for killing target cells
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
WO2020097445A1
(en)
|
2018-11-09 |
2020-05-14 |
Inari Agriculture, Inc. |
Rna-guided nucleases and dna binding proteins
|
|
WO2020123887A2
(en)
|
2018-12-14 |
2020-06-18 |
Pioneer Hi-Bred International, Inc. |
Novel crispr-cas systems for genome editing
|
|
KR102925054B1
(ko)
|
2018-12-20 |
2026-02-10 |
리제너론 파마슈티칼스 인코포레이티드 |
뉴클레아제-매개 반복부 팽창
|
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US12605398B2
(en)
|
2019-01-28 |
2026-04-21 |
The Administrators Of The Tulane Educational Fund |
CRISPR-based compositions for treating vascular disorders
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
|
MX2021010559A
(es)
|
2019-03-07 |
2021-12-15 |
Univ California |
Polipéptidos efectores de crispr-cas y métodos de uso de estos.
|
|
EP3769090B1
(en)
|
2019-03-18 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
|
CN120648640A
(zh)
|
2019-03-18 |
2025-09-16 |
瑞泽恩制药公司 |
用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
|
|
WO2020191233A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
AU2020256225B9
(en)
|
2019-04-03 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
KR102661779B1
(ko)
|
2019-04-04 |
2024-04-30 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
|
|
RU2771374C1
(ru)
|
2019-04-04 |
2022-05-04 |
Редженерон Фармасьютикалс, Инк. |
Способы для бесшовного внесения целевых модификаций в направленные векторы
|
|
JP7641233B2
(ja)
|
2019-04-12 |
2025-03-06 |
アストラゼネカ・アクチエボラーグ |
改善された遺伝子編集のための組成物及び方法
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
MX2021015122A
(es)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Animales no humanos que comprenden un locus de albumina humanizado.
|
|
CN113906134B
(zh)
|
2019-06-14 |
2025-06-24 |
瑞泽恩制药公司 |
Tau蛋白病模型
|
|
WO2021026294A1
(en)
|
2019-08-06 |
2021-02-11 |
Children's Medical Center Corporation |
Methods and compositions for reconstituting microglia
|
|
EP3783104A1
(en)
*
|
2019-08-20 |
2021-02-24 |
Kemijski Institut |
Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
|
|
EP4028063A1
(en)
|
2019-09-13 |
2022-07-20 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
DK3812472T3
(da)
|
2019-10-21 |
2023-02-20 |
Univ Freiburg Albert Ludwigs |
Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
|
|
US11331333B2
(en)
|
2019-11-08 |
2022-05-17 |
Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin |
Treatment of aberrant fibroblast proliferation
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
WO2021108561A1
(en)
*
|
2019-11-25 |
2021-06-03 |
La Jolla Institute For Immunology |
Methods and compositions for modulating heterochromatin dysfunction, genomic instability, and associated conditions
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
EP4073249A1
(en)
|
2019-12-11 |
2022-10-19 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
CN111088357B
(zh)
*
|
2019-12-31 |
2022-09-20 |
深圳大学 |
针对escc的肿瘤标志物及其应用
|
|
WO2021151085A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
|
WO2021151073A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
|
|
EP4097251A1
(en)
|
2020-01-29 |
2022-12-07 |
10X Genomics, Inc. |
Compositions and methods for analyte detection
|
|
CN115427568A
(zh)
|
2020-02-12 |
2022-12-02 |
麻省眼耳科医院 |
Rp1相关视网膜变性的基于单倍型的治疗
|
|
KR20230004456A
(ko)
|
2020-03-04 |
2023-01-06 |
리제너론 파아마슈티컬스, 인크. |
면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
|
|
EP4114952A4
(en)
*
|
2020-03-05 |
2024-05-08 |
Board of Regents of the University of Nebraska |
Crispr/cas9 system for multistrain hiv-1 treatment
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
EP4133069A2
(en)
*
|
2020-04-08 |
2023-02-15 |
Astrazeneca AB |
Compositions and methods for improved site-specific modification
|
|
MX2022012683A
(es)
*
|
2020-04-09 |
2023-01-11 |
Verve Therapeutics Inc |
Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
|
|
JP2023524976A
(ja)
*
|
2020-05-04 |
2023-06-14 |
エディタス・メディシン、インコーポレイテッド |
必須遺伝子ノックインによる選択
|
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
|
|
US20230279438A1
(en)
|
2020-05-13 |
2023-09-07 |
Inserm (Institut National De La Santé Et La Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
|
WO2021246165A1
(ja)
*
|
2020-06-03 |
2021-12-09 |
国立大学法人広島大学 |
Ｏａｓｉｓ遺伝子の脱メチル化のための核酸及びそれを用いた脱メチル化方法
|
|
MX2022015284A
(es)
*
|
2020-06-05 |
2023-01-19 |
Univ California |
Composiciones y metodos para la edicion del epigenoma.
|
|
WO2022008935A1
(en)
|
2020-07-10 |
2022-01-13 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US20230293726A1
(en)
|
2020-08-11 |
2023-09-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method for the treatment of wwox associated diseases
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
KR102674574B1
(ko)
*
|
2020-09-02 |
2024-06-13 |
한국과학기술연구원 |
Cas9을 위한 신규 tracrRNA 시스템
|
|
US20240016855A1
(en)
|
2020-10-13 |
2024-01-18 |
Centre National De La Recherche Scientifique (Cnrs) |
Targeted-antibacterial-plasmids combining conjugation and crispr/cas systems and uses thereof
|
|
RU2762831C1
(ru)
*
|
2020-10-26 |
2021-12-23 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
Молекула рнк-проводника для геномного редактирования протомоторной области гена vrn-a1 однодольных зерновых с применением системы crispr/cas9
|
|
CN112430622A
(zh)
*
|
2020-10-26 |
2021-03-02 |
扬州大学 |
一种FokI和dCpf1融合蛋白表达载体及其介导的定点基因编辑方法
|
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
KR20220082186A
(ko)
|
2020-12-10 |
2022-06-17 |
한세준 |
유,무선 충전이 가능한 보조배터리형 uv-led살균기
|
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US12171813B2
(en)
|
2021-02-05 |
2024-12-24 |
Christiana Care Gene Editing Institute, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
WO2022180153A1
(en)
|
2021-02-25 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
|
KR102882704B1
(ko)
|
2021-03-03 |
2025-11-12 |
중앙대학교 산학협력단 |
CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
|
|
CN113846019B
(zh)
*
|
2021-03-05 |
2023-08-01 |
海南师范大学 |
一种海洋微拟球藻靶向表观基因组遗传调控方法
|
|
EP4095243A1
(en)
|
2021-05-25 |
2022-11-30 |
European Molecular Biology Laboratory |
System for hybridization-based precision genome cleavage and editing, and uses thereof
|
|
US20240384246A1
(en)
|
2021-05-27 |
2024-11-21 |
Astrazeneca Ab |
Ca s9 effector proteins with enhanced stability
|
|
WO2022261292A1
(en)
|
2021-06-10 |
2022-12-15 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4387992A1
(en)
|
2021-08-20 |
2024-06-26 |
Wisconsin Alumni Research Foundation |
Nonviral generation of genome edited chimeric antigen receptor t cells
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
EP4596696A3
(en)
|
2021-09-28 |
2025-08-27 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
EP4409000A1
(en)
|
2021-09-28 |
2024-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
JP2024537991A
(ja)
|
2021-10-14 |
2024-10-18 |
アーセナル バイオサイエンシズ インコーポレイテッド |
共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
|
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
|
US20240415980A1
(en)
|
2021-10-28 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
CA3237303A1
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20250113795A1
(en)
*
|
2022-01-20 |
2025-04-10 |
Inari Agriculture Technology, Inc. |
Improved soybean explant preparation and transformation
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
|
CA3242731A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
US20250152677A1
(en)
|
2022-02-14 |
2025-05-15 |
Institut National de la Santé et de la Recherche Médicale |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
|
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
US20250302998A1
(en)
|
2022-05-09 |
2025-10-02 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
US20250241956A1
(en)
|
2022-05-10 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from beta-thalassemia
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
JP2025521154A
(ja)
|
2022-05-31 |
2025-07-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
JP2025525569A
(ja)
|
2022-07-18 |
2025-08-05 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
遺伝子編集成分、システム、及び使用方法
|
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
KR20250077608A
(ko)
|
2022-08-19 |
2025-05-30 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
KR20250075694A
(ko)
|
2022-09-28 |
2025-05-28 |
리제너론 파마슈티칼스 인코포레이티드 |
세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
|
|
WO2024084025A1
(en)
|
2022-10-21 |
2024-04-25 |
Keygene N.V. |
Rna transfection in plant cells with modified rna
|
|
EP4612184A1
(en)
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
KR20250116795A
(ko)
|
2022-11-14 |
2025-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
|
|
CN115820603B
(zh)
*
|
2022-11-15 |
2024-07-05 |
吉林大学 |
一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
|
|
WO2024121354A1
(en)
|
2022-12-08 |
2024-06-13 |
Keygene N.V. |
Duplex sequencing with covalently closed dna ends
|
|
KR20250128349A
(ko)
*
|
2022-12-23 |
2025-08-27 |
에피제닉 테라퓨틱스 피티이 리미티드 |
융합체 및 이의 용도
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
JP2026506554A
(ja)
|
2023-02-06 |
2026-02-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
多重塩基編集による遺伝子改変造血幹細胞の濃縮
|
|
CN116376975B
(zh)
*
|
2023-02-27 |
2024-05-14 |
中国科学院脑科学与智能技术卓越创新中心 |
激活异染色质基因的方法及应用
|
|
TW202436622A
(zh)
|
2023-03-06 |
2024-09-16 |
美商英特利亞醫療公司 |
用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法
|
|
CN118684781A
(zh)
*
|
2023-03-21 |
2024-09-24 |
深圳赫兹生命科学技术有限公司 |
GnRH-VLP重组去势疫苗及其制备方法
|
|
EP4689155A1
(en)
|
2023-03-29 |
2026-02-11 |
Astrazeneca AB |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
EP4689157A1
(en)
|
2023-04-04 |
2026-02-11 |
Keygene N.V. |
Linkers for duplex sequencing
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
KR20260032927A
(ko)
|
2023-06-30 |
2026-03-10 |
리제너론 파마슈티칼스 인코포레이티드 |
상동성 지향 복구를 증가시키는 방법 및 조성물
|
|
WO2025017033A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -115 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
WO2025017030A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -200 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
KR20250016657A
(ko)
*
|
2023-07-21 |
2025-02-04 |
한국화학연구원 |
dxCas9 및 CRP 유도체를 포함하는, 표적 유전자 발현 조절 시스템 및 이의 제조방법
|
|
CN121693566A
(zh)
|
2023-07-28 |
2026-03-17 |
瑞泽恩制药公司 |
使用bGH-SV40L串联PolyA在单向基因插入期间增强转基因表达
|
|
IL326018A
(en)
|
2023-07-28 |
2026-03-01 |
Regeneron Pharma |
Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038642A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying cd70
|
|
IL326191A
(en)
|
2023-08-14 |
2026-03-01 |
Intellia Therapeutics Inc |
Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
WO2025261475A1
(zh)
*
|
2024-06-21 |
2025-12-26 |
益杰立科(上海)生物科技有限公司 |
靶向血管内皮生长因子的工程化基因转录阻抑工具及用途
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026077659A1
(en)
|
2024-09-17 |
2026-04-16 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through epigenome editing
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026072529A1
(en)
|
2024-09-24 |
2026-04-02 |
University Of Florida Research Foundation, Incorporated |
Mettl7a for improved embryo competence
|
|
WO2026080515A2
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cells and cell lines and methods of use thereof
|
|
WO2026083309A1
(en)
|
2024-10-17 |
2026-04-23 |
Astrazeneca Ab |
Use of inhibitors or modulators of artemis in gene editing
|
|
CN121554544B
(zh)
*
|
2026-01-23 |
2026-04-28 |
成都医学院 |
一种NFT蛋白及其制备方法和应用，以及一种NusA或NusA融合蛋白的纯化方法
|